Saving lives and making healthcare delivery more effective
We developed OneRNA® Platform to provide better treatment options for patients. We can also use this platform to de-risk, accelerate,and improve drug discovery and development processes for biotech and pharma. In the future, we can envision completely individualized RNA Therapeutics.
Standard of care is static
and leaves most patients behind
From a genetic perspective, every cancer is unique. Yet, most patients are offered a standard treatment based on tissue of origin and stage. In many cases, the same genetic alteration can be driving breast cancer in one patient and lung cancer in another, opening up for many more treatment options.
Sequencing provides a paradigm shift
to a dynamic treatment method
Using a single biomarker to improve patient selection was a breakthrough 25 years ago when the term personalized was coined. Testing did improve response rates. However, new sequencing biomarker analysis methods can analyze all possible genes in one test. OneRNA® is dynamic and
1) Identifies FDA-approved drugs for the individual patient in practically all patients. OneRNA(R) is validated in breast and ovarian cancer, and 2) Follows the patient's response in a liquid biopsy sample (in development)
RNA is more informative than DNA
DNA is static while RNA is dynamic
DNA panels used in cancer tissue analyses up to 500 genes typically only identify one drug in 40% of the cases. Some cancers have no or very few mutations; thus, DNA testing is not very useful. We don't like guessing, and therefore, we analyze ALL the +20,000 mRNA’s in the sample. This makes our OneRNA® platform the most powerful platform in the industry and it enables the implementation of AI into standard of care.
The OneRNA® Platform
We have solved the 3 key issues enabling RNA sequencing in real clinical samples
1) RNA is unstable in real clinical samples; 2) To identify abnormal genes, a 2nd biopsy is required, which would create friction and add cost; and finally, 3) Translate abnormal genes to treatment options. We resolved all three issues and clinically validated the platform from sample acquisition to clinical report delivery, making it exponentially scalable. The OneRNA® drug database can also assist the oncologist in the community setting using more biomarker testing. OneRNACloud® is delivered in a HIPAA and CLIA-compliant fashion.
OneRNA® AI enables delivery of care
Partner with us to improve outcomes
RNA algorithms have already been developed using less powerful platforms. For example, OncoTypeDx is an algorithm using PCR of 16 genes that helps patients and their oncologists comfortably opt out of chemo for very early breast cancer patients. However, OneRNA® superpowers the process of developing such algorithms because all RNAs are analyzed in all samples. OneRNA® enables AI-powered healthcare by combining OneRNA® data with outcome data to produce better outcomes. OneRNA® AI can then identify patients who will benefit from the standard of care and provide other options for patients who will not.
